Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

4.320
+0.62016.76%
Volume:4.35M
Turnover:18.12M
Market Cap:2.93B
PE:-9.83
High:4.380
Open:3.830
Low:3.760
Close:3.700
52wk High:8.160
52wk Low:2.680
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:3.12
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.439
ROE:-32.03%
ROA:-11.48%
PB:3.95
PE(LYR):-9.83
PS:24.09

Loading ...

Antengene Corp Intends to Repurchase up to 67.92 Million Shares

Reuters
·
Jun 25

Antengene Plans HK$50.00 Million On-Market Share Buyback Covering Up to 10% of Issued Shares

Bulletin Express
·
Jun 25

ANTENGENE-B to Initiate On-Market Share Buyback Program

Stock News
·
Jun 25

Antengene Plans up to HK$50 Million On-market Share Buyback

Reuters
·
Jun 25

Antengene Corp - Intends to Repurchase up to 67.92 Mln Shares

THOMSON REUTERS
·
Jun 25

Antengene Corp - Board Resolves to Repurchase Shares up to HK$50 Mln Aggregate Consideration

THOMSON REUTERS
·
Jun 25

Antengene to Spin Off TCE Assets into New Entity for Global Expansion

Deep News
·
Jun 22

BRIEF-Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106

Reuters
·
Jun 22

Antengene-B Inks Exclusive Licensing Deal with K2 Therapeutics for ATG-106 and Grants Option for Undisclosed Bispecific TCE

Stock News
·
Jun 22

Antengene clinches USD 20.00 million global licensing deal with K2 Therapeutics for ATG-106; milestones may add USD 960.50 million and mirrors terms for optional second TCE

Bulletin Express
·
Jun 22

Antengene licenses ATG-106 bispecific T-cell engager to MPM BioImpact’s K2 Therapeutics for USD 20 million upfront

Reuters
·
Jun 22

Antengene Corp - to Receive About $20 Mln Upfront and Near-Term Consideration

THOMSON REUTERS
·
Jun 22

Antengene Corp - Enters Exclusive License Agreement With K2 Therapeutics for Atg-106

THOMSON REUTERS
·
Jun 22

Antengene-B Announces Appointment of New Co-Company Secretaries

Stock News
·
Jun 10

Antengene Reshuffles Joint Company Secretaries and Secures Three-Year HKEX Compliance Waiver

Bulletin Express
·
Jun 10

Antengene names Ying Liu, Chin Hei Lam as joint company secretaries, replacing Yang Cao, Wai Chiu Wong

Reuters
·
Jun 10

BRIEF-Antengene Says China NMPA Approves IND Application For Phase I Study Of ATG-201

Reuters
·
Jun 10

Antengene Secures China IND Approval for Autoimmune Disease Drug

MT Newswires Live
·
Jun 10

ANTENGENE-B Receives Chinese IND Approval for ATG-201 in Autoimmune Disease Treatment

Stock News
·
Jun 10

Antengene Gains NMPA IND Clearance for ATG-201 CD19×CD3 T-Cell Engager Targeting Autoimmune Diseases

Bulletin Express
·
Jun 10